Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Core Viewpoint - Lixte Biotechnology Holdings, Inc. has announced a registered direct offering to raise approximately $4.3 million through the sale of Common Stock and warrants, aimed at advancing its cancer treatment initiatives [1][3]. Group 1: Offering Details - The offering includes the sale of 1,051,342 Common Units, each comprising one share of Common Stock or one Pre-Funded Warrant and one Common Warrant to purchase one share of Common Stock at an exercise price of $3.96 [2]. - The public offering price per Common Unit is set at $4.09, with Pre-Funded Units priced slightly higher at $4.08999 [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised, while the Common Warrants are also immediately exercisable and will expire 60 months after issuance [2]. Group 2: Financial Implications - The aggregate gross proceeds from the offering are expected to be approximately $4.3 million, which will be used for general corporate purposes and working capital [3]. - The transaction is anticipated to close on or about December 19, 2025, pending customary closing conditions [3]. Group 3: Company Background - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies, with its lead compound, LB-100, showing promise in enhancing chemotherapy and immunotherapy outcomes [7][8]. - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, supported by a comprehensive patent portfolio [8].